5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
Alan K. Davis, Sara So, Rafael Lancelotta, Joseph P Barsuglia, Roland R. Griffiths
The American Journal of Drug and Alcohol Abuse 2019 DOI: 10.1080/00952990.2018.1545024 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 362 |
| Population | Adults who used 5-MeO-DMT in a group setting with structured procedures |
| Intervention | 5-MeO-DMT |
| Topics | 5-MeO-DMT Anxiety Depression DMT |
| Keywords | 5-MEO-DMT 5-MEO-DMT Unique tryptamine Improvement Potential benefits Psychedelic tryptamines psychedelic Profound subjective effects |
| Citations | 141 |
| Key findings | Most respondents with prior diagnoses of depression or anxiety reported improvement after 5-MeO-DMT use, with greater improvement associated with mystical experience intensity and spiritual significance. |
Abstract
A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. We examined self-reported improvement in depression and anxiety among people who use 5-MeO-DMT in a group setting with structured procedures guiding dose and administration of 5-MeO-DMT. Such procedures also include activities for the preparation of, and support during/following sessions, which are similar to procedures used in clinical trials of hallucinogen administration. Next, we examined whether depression or anxiety were improved following use, and whether the acute subjective effects (mystical/challenging) or beliefs about the 5-MeO-DMT experience were associated with improvements in these conditions. Respondents (n = 362; Mage = 47.7; Male = 55%; White/Caucasian = 84%) completed an anonymous web-based survey. Of those reporting having been diagnosed with depression (41%) or anxiety (48%), most reported these conditions were improved (depression = 80%; anxiety = 79%) following 5-MeO-DMT use, and fewer reported they were unchanged (depression = 17%; anxiety = 19%) or worsened (depression = 3%; anxiety = 2%). Improvement in depression/anxiety conditions were associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning of the 5-MeO-DMT experience. There were no associations between depression or anxiety improvement and the intensity of acute challenging physical/psychological effects during the 5-MeO-DMT experience. Future prospective controlled clinical pharmacology studies should examine the safety and efficacy of 5-MeO-DMT administration for relieving depression and anxiety.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Among respondents with prior depression diagnoses, 80% reported improvement after 5-MeO-DMT, and improvement was associated with greater mystical experience intensity and spiritual significance.
Synthesized
Comparable studies
Other cross-sectional and survey studies on 5-MeO-DMT, most cited first.
Citations in the library
Cited by 124
- Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science 2020
- Cessation and reduction in alcohol consumption and misuse after psychedelic use Journal of Psychopharmacology May 14, 2019
- Long-term effects of psychedelic drugs: A systematic review Neuroscience & Biobehavioral Reviews March 16, 2020
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology April 13, 2019
and 119 more in the library
Cites 19
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
and 14 more in the library